Practices of US health insurance companies concerning MS therapies interfere with shared decision-making and harm patients
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 16, 2015
- Accepted October 7, 2015
- First Published December 10, 2015.
Article Versions
- Previous version (December 10, 2015 - 13:00).
- You are viewing the most recent version of this article.
Author Disclosures
- Dennis N. Bourdette, MD,
- Daniel M. Hartung, PharmD, MPH and
- Ruth H. Whitham, MD
- Dennis N. Bourdette, MD,
NONE
NONE
NONE
Current Neurology and Neuroscience Reports, Section Editor, 2008-present; Autoimmune Diseases, Associate Editor, 2009-present; Neurology, Member Editorial Board, 2013-present present. I receive no compensation for any of these activities.
I have a use patent pending for the treatment of multiple sclerosis with cyclic peptide derivatives of cyclosporin. I have a patent pending for a thyromimetic drug for stimulating remyelination in multiple sclerosis.
NONE
NONE
I have served as a consultant to Teva Neurosciences within the past 24 months; Biogen; Genentech
NONE
NONE
NONE
Biogen
Department of Veterans Affairs/Rehabilitation R&D, Merit Review, 1/1/12-12/31/15 National MS Society April 2015- present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Daniel M. Hartung, PharmD, MPH and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Providence Health Systems. Consulting services
NONE
NONE
NONE
NONE
(1) AHRQ, 1K12HS019456-01; Career development award 2010 - 2013 (2) CDC/NIDA, 1U01CE002500-01; Principal investigator, 2014 - 2016 (3) AHRQ, 1R18HS024227-01; Principal investigator, 2015-2018
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ruth H. Whitham, MD
I am a member of the data safety monitoring board for two clinical trials for treatment of neuromyelitis optica, sponsored by Chugai Pharmaceutical Co.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Department of Neurology (DNB, RHW), Oregon Health & Science University, Portland; Multiple Sclerosis Center of Excellence West (DNB, RHW), VA Portland Health Care System, OR; and The College of Pharmacy (DMH), Oregon State University/Oregon Health & Science University, Portland.
- Correspondence to:
bourdett{at}ohsu.edu
Article usage
The Nerve!: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Ann Yeh and Dr. Daniela Castillo Villagrán
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Special Article
Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosisReport of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of NeurologyAlexander Rae-Grant, Gregory S. Day, Ruth Ann Marrie et al.Neurology, April 23, 2018 -
Article
Effect of generic glatiramer acetate on spending and use of drugs for multiple sclerosisDaniel M. Hartung, Kirbee A. Johnston, Jonah Geddes et al.Neurology, January 15, 2020 -
Article
A survey of risk tolerance to multiple sclerosis therapiesRobert J. Fox, Carol Cosenza, Lauren Cripps et al.Neurology, March 13, 2019 -
Contemporary Issues
The cost of multiple sclerosis drugs in the US and the pharmaceutical industryToo big to fail?Daniel M. Hartung, Dennis N. Bourdette, Sharia M. Ahmed et al.Neurology, April 24, 2015